Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)

NCT06832904 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Breast Cancer
Neoadjuvant Therapy
Pyrotinib

Interventions

DRUG: pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy

Sponsor

First Affiliated Hospital of Zhejiang University